Amgen Inc. $AMGN Shares Sold by Hollow Brook Wealth Management LLC

Hollow Brook Wealth Management LLC cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 54.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,312 shares of the medical research company’s stock after selling 1,548 shares during the period. Hollow Brook Wealth Management LLC’s holdings in Amgen were worth $429,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. High Note Wealth LLC grew its stake in shares of Amgen by 5.8% during the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 28 shares in the last quarter. TAGStone Capital Inc. grew its stake in shares of Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after acquiring an additional 28 shares in the last quarter. Verus Capital Partners LLC grew its stake in shares of Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after acquiring an additional 28 shares in the last quarter. Destination Wealth Management grew its stake in shares of Amgen by 2.1% during the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 29 shares in the last quarter. Finally, West Family Investments Inc. grew its stake in shares of Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Down 1.3%

NASDAQ:AMGN opened at $350.53 on Tuesday. The company has a market capitalization of $189.18 billion, a price-to-earnings ratio of 24.39, a price-to-earnings-growth ratio of 3.56 and a beta of 0.42. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The stock has a 50-day simple moving average of $341.03 and a 200 day simple moving average of $345.86. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts predict that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. UBS Group raised their target price on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Royal Bank Of Canada lifted their price target on Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Leerink Partners reiterated a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research note on Thursday, March 5th. Truist Financial lifted their price target on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research note on Friday, May 1st. Finally, Barclays initiated coverage on Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $354.42.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.